secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001193125-23-133192
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q1 net loss narrows to $27.4M; cash $207.6M, pipeline advances with RNA editing candidate toward CTA
--------------------------------------------------------------------------------

- Q1 revenue $12.9M from GSK/Takeda collaborations vs $1.8M a year ago; net loss $27.4M vs $37.8M.
- Cash $207.6M at March 31, 2023 (up from $88.5M Dec 2022) provides runway into 2025, plus potential GSK milestones.
- WVE-006, first-in-class RNA editing candidate for AATD, on track for CTA submissions in 2H 2023.
- WVE-N531 for DMD: potentially registrational Phase 2 trial to start 2023 with dystrophin primary endpoint; data expected 2024.
- WVE-003 HD data delayed to 2H 2023 due to cyber attack at assay vendor; no Wave data compromised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/0001193125-23-133192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523133192/d42603d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-133192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer